We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific Sustains Momentum in the PFA Market: What's Next?
Read MoreHide Full Article
Key Takeaways
BSX advances in PFA with FARAPULSE showing strong growth and favorable trial results.
BSX saw U.S. double-digit FARAPULSE growth aided by the adoption of OPAL HDx and integrated NAV technology.
BSX gained FDA label expansion and advanced PFA tools like FARAPOINT to broaden AF treatment.
Atrial fibrillation (AF or AFib) is one of the most common abnormal heart rhythms, affecting nearly 38 million people worldwide — a figure projected to nearly triple by 2030. Boston Scientific (BSX - Free Report) holds a leading position in left atrial appendage closure (LAAC) devices while expanding its presence in pulsed field ablation (PFA), the fastest-growing segment of AF treatment. The company’s FARAPULSE, since its launch in the United States in 2024, continues to be the widely used PFA technology.
To date, more than 500,000 patients have been treated with the system, along with consistent and reproducible real-world results. Newly published one-year results from the FARADISE trial reinstates this, showing favorable procedural and safety outcomes and clinical effectiveness across ablation strategies and AF types.
In the third quarter of 2025, FARAPULSE delivered strong double-digit growth in the United States, supported by the accelerating adoption of the OPAL HDx mapping system, with one in three FARAPULSE accounts now using the integrated FARAWAVE NAV and OPAL device. Additionally, the FDA approved the expanded labeling for the system in the treatment of drug-refractory, symptomatic, persistent AF. It was supported by clinical evidence from phase one of the ADVANTAGE AF clinical trial, which met both the primary safety and effectiveness endpoints.
Meanwhile, the positive 12-month primary endpoint results from the second phase of the ADVANTAGE are supporting the FARAPOINT PFA catheter as an adjunct technology to treat atrial flutter in patients with persistent Afib, which Boston Scientific plans to launch by year-end 2025. The company continues to invest to outpace the approximately 15% market growth expected through 2028 by advancing its ecosystem of innovative solutions across both the AF and non-AF segments of the market.
BSX’s Peer Updates
Abbott (ABT - Free Report) obtained CE Mark for its Volt PFA System in March this year. Recently, the company announced that its over-the-counter continuous glucose monitor (CGM) and app, Lingo, is now available for Android devices. Building on Lingo’s availability in Apple iOS devices, this expansion gives more people access to real-time glucose data, empowering informed choices that help support better energy, sleep, focus and overall well-being.
Medtronic (MDT - Free Report) is the only company with two distinct PFA offerings — PulseSelect and Affera Sphere-9. The company recently announced the FDA clearance of the Hugo robotic-assisted surgery system for urologic surgical procedures. The clearance brings a versatile robotic-assisted platform to U.S. surgeons and health systems seeking to expand soft-tissue robotic surgery programs and access to minimally invasive care.
BSX Price Performance, Valuation and Estimates
In the past year, Boston Scientific shares have risen 2.5% against the industry’s 3.3% fall.
Image Source: Zacks Investment Research
BSX shares are trading at a forward five-year Price-to-Earnings (P/E) ratio of 27.06, above its median but lower than the industry average.
Image Source: Zacks Investment Research
Earnings estimates for Boston Scientific are showing an upward trend.
Image: Bigstock
Boston Scientific Sustains Momentum in the PFA Market: What's Next?
Key Takeaways
Atrial fibrillation (AF or AFib) is one of the most common abnormal heart rhythms, affecting nearly 38 million people worldwide — a figure projected to nearly triple by 2030. Boston Scientific (BSX - Free Report) holds a leading position in left atrial appendage closure (LAAC) devices while expanding its presence in pulsed field ablation (PFA), the fastest-growing segment of AF treatment. The company’s FARAPULSE, since its launch in the United States in 2024, continues to be the widely used PFA technology.
To date, more than 500,000 patients have been treated with the system, along with consistent and reproducible real-world results. Newly published one-year results from the FARADISE trial reinstates this, showing favorable procedural and safety outcomes and clinical effectiveness across ablation strategies and AF types.
In the third quarter of 2025, FARAPULSE delivered strong double-digit growth in the United States, supported by the accelerating adoption of the OPAL HDx mapping system, with one in three FARAPULSE accounts now using the integrated FARAWAVE NAV and OPAL device. Additionally, the FDA approved the expanded labeling for the system in the treatment of drug-refractory, symptomatic, persistent AF. It was supported by clinical evidence from phase one of the ADVANTAGE AF clinical trial, which met both the primary safety and effectiveness endpoints.
Meanwhile, the positive 12-month primary endpoint results from the second phase of the ADVANTAGE are supporting the FARAPOINT PFA catheter as an adjunct technology to treat atrial flutter in patients with persistent Afib, which Boston Scientific plans to launch by year-end 2025. The company continues to invest to outpace the approximately 15% market growth expected through 2028 by advancing its ecosystem of innovative solutions across both the AF and non-AF segments of the market.
BSX’s Peer Updates
Abbott (ABT - Free Report) obtained CE Mark for its Volt PFA System in March this year. Recently, the company announced that its over-the-counter continuous glucose monitor (CGM) and app, Lingo, is now available for Android devices. Building on Lingo’s availability in Apple iOS devices, this expansion gives more people access to real-time glucose data, empowering informed choices that help support better energy, sleep, focus and overall well-being.
Medtronic (MDT - Free Report) is the only company with two distinct PFA offerings — PulseSelect and Affera Sphere-9. The company recently announced the FDA clearance of the Hugo robotic-assisted surgery system for urologic surgical procedures. The clearance brings a versatile robotic-assisted platform to U.S. surgeons and health systems seeking to expand soft-tissue robotic surgery programs and access to minimally invasive care.
BSX Price Performance, Valuation and Estimates
In the past year, Boston Scientific shares have risen 2.5% against the industry’s 3.3% fall.
Image Source: Zacks Investment Research
BSX shares are trading at a forward five-year Price-to-Earnings (P/E) ratio of 27.06, above its median but lower than the industry average.
Image Source: Zacks Investment Research
Earnings estimates for Boston Scientific are showing an upward trend.
Image Source: Zacks Investment Research
BSX stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.